On comparison of serum UA, P on D0 with D7 post-chemotherapy, we found significantly higher than from baseline suggesting that induction chemotherapy
is the main risk factor for developing TLS.
According to the company, the US FDA approved VENCLEXTA in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
. This indication is approved under accelerated approval based on response rates.
In patients with this type of B-ALL, screening for targetable kinase alterations is the most critical aspect of the diagnostic algorithm, as demonstrated in the subset of children with PDGFRB translocations and primary resistance to induction chemotherapy
We report herein a case of NOMI due to induction chemotherapy
with TPF for oropharyngeal carcinoma.
Hence induction chemotherapy
followed by local treatment in the form of radiation or CCRT seems to be a logical strategy.
All patients underwent induction chemotherapy
(i.e., "3 + 7") with cytarabine 100mg/mq, intravenously, on days 1 to 7 and an anthracycline [daunorubicin 60 mg/mq on days 1 to 3 or mitoxantrone 10 mg/mq on days 1 to 3] and thereafter intermediate dose cytarabine for consolidation (up to 2 cycles)  or at higher doses (FLAG-Ida for all patients) as a bridge to allotransplantation [17,18] fornonresponder patients.
We included these three studies in the meta-analysis and found that induction chemotherapy
before chemoradiotherapy did not significantly improve the overall pCR.
He was started on aggressive induction chemotherapy
with a 7 + 3 regimen (7 days of cytarabine at 100mg/[m.sup.2] plus 3 days of idarubicin at 12mg/[m.sup.2]) in addition to resuming dasatinib.
Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing induction chemotherapy
are severely immunocompromised and therefore at risk of developing invasive fungal infections (IFI).
The patient received five cycles of induction chemotherapy
, high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (auto-PBSCT), followed by surgical resection of the primary tumor together with renal biopsy, and finally cranial irradiation (Table 1).
Group A included patients treated with induction chemotherapy
with 2.5 cycles of fluorouracil, leucovorin, and cisplatin followed by surgery while Group B treatment consisted of 2 cycles of chemotherapy of fluorouracil, leucovorin, and cisplatin and 3 weeks of combined chemoradiotherapy with cisplatin and etoposide followed by surgery.
Although there have been landmark targeted therapies developed in other hematologic malignancies, such as imatinib for chronic myeloid leukemia and ibrutinib in chronic lymphocytic leukemia, induction chemotherapy
for AML has not changed significantly for several decades [1, 2].